✦ LIBER ✦

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial

✍ Scribed by Rene Westhovens; David Yocum; John Han; Alberto Berman; Ingrid Strusberg; Piet Geusens; Mahboob U. Rahman; START Study Group

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 129 KB
Volume: 54
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.21734

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy and safety of rituximab in

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

✍ Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB 👁 2 views

Evaluation of the safety of rituximab in

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial

✍ Maria W. Greenwald; William J. Shergy; Jeffrey L. Kaine; Marianne T. Sweetser; K 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 2 views

Treatment of rheumatoid arthritis with m

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: Results of a two-year, randomized, double-blind, placebo-controlled trial

✍ James R. O'Dell; Robert Leff; Gail Paulsen; Claire Haire; Jack Mallek; P. James 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

Long-term safety and maintenance of clin

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

✍ George Nuki; Barry Bresnihan; Moraye B. Bear; Dorothy McCabe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

Clinical and radiographic outcomes of fo

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial

✍ Y. P. M. Goekoop-Ruiterman; J. K. De Vries-Bouwstra; C. F. Allaart; D. Van Zeben 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB 👁 1 views

Assessment of antibodies to double-stran

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials

✍ P. J. Charles; R. J. T. Smeenk; J. De Jong; M. Feldmann; R. N. Maini 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

Objective. To compare the incidence of antidouble-stranded DNA (anti-dsDNA) antibodies in rheumatoid arthritis (RA) patients receiving either single or multiple doses of a chimeric anti-tumor necrosis factor ␣ (anti-TNF␣) antibody or placebo infusions, with or without methotrexate, in open-label, ra